Research Article Zangarini, Rajan, Danilenko, Berry, Traversa & Veal References
1 Kase H, Iwahashi K, Matsuda Y. K-252a, a potent inhibitor of protein kinase C from microbial origin. J. Antibiot. (Tokyo) 39(8), 1059–1065 (1986).
2 Abdelbary AA, AbouGhaly MH. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box–Behnken design, in-vitro evaluation and in-vivo skin deposition study. Int. J. Pharm. 485(1–2), 235–243 (2015).
3 Roblin D, Yosipovitch G, Boyce B et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a Phase llb clinical trial in patients with psoriasis. Acta Derm. Venereol. 95(5), 542–548 (2015).
4 Young AL, Kellermayer R, Szigeti R, Teszas A, Azmi S, Celebi JT. CYLD mutations underlie Brooke–Spiegler, familial cylindromatosis, and multiple familial trichoepithelioma syndromes. Clin. Genet. 70(3), 246–249 (2006).
5
Saggar S, Chernoff KA, Lodha S et al. CYLD mutations in familial skin appendage tumours. J. Med. Genet. 45(5), 298–302 (2008).
6 Bignell GR, Warren W, Seal S et al. Identification of the familial cylindromatosis tumour suppressor gene. Nat. Genet. 25(2), 160–165 (2000).
7 Rajan N, Langtry JA, Ashworth A et al. Tumour mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumour induction. Arch. Dermatol. 145(11), 1277–1284 (2009).
8 Rajan N, Elliott R, Clewes O et al. Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours. Oncogene 30(41), 4243–4260 (2011).
9 Cheng TL, Chuang KH, Chen BM, Roffler SR. Analytical measurement of PEGylated molecules. Bioconjug. Chem. 23(5), 881–899 (2012).
10 Li H, Rose MJ, Holder JR, Wright M, Miranda LP, James CA. Direct quantitative analysis of a 20 kDa PEGylated human calcitonin gene peptide antagonist in cynomolgus monkey serum using in-source CID and UPLC-MS/MS. J. Am. Soc. Mass Spectrom. 22(9), 1660–1667 (2011).
11 Gong J, Gu X, Achanzar WE et al. Quantitative Analysis of Polyethylene Glycol (PEG) and PEGylated proteins in animal tissues by LC-MS/MS coupled with in-source CID. Anal. Chem. 86(15), 7642–7649 (2014).
12 European Medicines Agency. Guideline on bioanalytical method validation. Committee for Medicinal Products for Human Use (CHMP), London, UK (2011).
www.ema.europa.eu/docs
13 US FDA. Guidance for Industry Bioanalytical Method Validation. Center for Drug Evaluation and Research (CDER) (2001).
www.fda.gov/downloads
28825
Bioanalysis (2017) 9(3)
future science group
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58
